Navigation Links
Abbott Announces Positive Nine-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

improved radial strength, which is intended to maintain vessel expansion so blood can flow through.

"Not only is the ABSORB trial beginning to show that bioabsorbable technology, when applied to coronary stents, can work -- it can also provides a foundation for future interventional medical innovation," said John M. Capek, Ph.D., senior vice president, Abbott Vascular. "Five years ago, the technology and 'know-how' to make a fully functioning bioabsorbable drug eluting stent didn't exist, but every success in the ABSORB trial brings us one step closer to providing this important new treatment option to physicians for their patients."

About the ABSORB Clinical Trial

The ABSORB trial is a prospective, non-randomized (open label) study designed to enroll up to 60 patients in Belgium, Denmark, France, New Zealand, Poland and The Netherlands. Key endpoints of the study include assessments of safety; MACE and stent thrombosis (blood clot formation) rates at 30, 180 and 270 days, with an annual follow-up for up to five years, and successful deployment of the bioabsorbable drug eluting stent. Other key endpoints of the study include follow-up measurements assessed by X-ray angiography, intravascular ultrasound (IVUS), and state-of-the-art imaging modalities at 180 days and two years.

In March, six-month results from the first 30 patients in the ABSORB trial were presented at the of Cardiology conference, demonstrating no stent thrombosis and a low (3.3 percent, one patient) of Major Adverse Cardiac Events (MACE), such as heart attack or repeat interventional medical treatment.

For images of Abbott's investigational bioabsorbable stent and other information, please visit the company's online newsroom at http://www.abbottvascular.com/presskit.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses.
'"/>




Page: 1 2 3

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
3. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
4. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
5. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/29/2014)... SAN DIEGO , 29. ... Ltd. (nachstehend Daiichi Sankyo) (TSE: 4568) und ... gaben heute gemeinsam eine definitive Fusionsvereinbarung bekannt, ... von Ambit Biosciences für 15 US-Dollar je ... anschließenden Zusammenschluss mit einem Tochterunternehmen von Daiichi ...
(Date:9/29/2014)... IRVING, Texas , Sept. 29, 2014 /PRNewswire/ ... 340B Drug Pricing Program, has announced that it ... Services Administration (HRSA) to continue serving in its ... 2019. Apexus, which has held this position for ... with more than 25,000 safety-net provider locations, drug ...
(Date:9/29/2014)... SEATTLE , Sept. 29, 2014 ... leverages Next Generation Sequencing to profile the adaptive ... a Scientific Advisory Board to provide strategic and ... diagnostic suite of assays in the diagnosis and ... initial focus of the SAB will be to ...
Breaking Medicine Technology:Daiichi Sankyo wird Ambit Biosciences übernehmen 2Daiichi Sankyo wird Ambit Biosciences übernehmen 3Daiichi Sankyo wird Ambit Biosciences übernehmen 4Daiichi Sankyo wird Ambit Biosciences übernehmen 5Daiichi Sankyo wird Ambit Biosciences übernehmen 6Daiichi Sankyo wird Ambit Biosciences übernehmen 7Daiichi Sankyo wird Ambit Biosciences übernehmen 8Apexus Wins HRSA Contract to Remain Prime Vendor of 340B Program 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 3
... Medical Inc. (TMI),announced today that it has been ... commercialize in Europe the Antares(TM) Coronary,Stent System, a ... use,at or near coronary bifurcations., Representing the ... potential use in a quarter of the 2.2 ...
... Line Clinical Results Expected in November 2008, BOTHELL, ... ) announced today the completion of patient enrollment and ... evaluate the safety and,efficacy of its formulation of 12-hour ... expects to report top-line,results from this pivotal trial in ...
Cached Medicine Technology:TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3
(Date:9/30/2014)... KY (PRWEB) September 30, 2014 Up ... people in the United States alone have sleep apnea. ... and of those treated, many cannot tolerate their prescribed ... supplied through a nasal mask) – which supports the ... night’s sleep has become especially valuable, and increasingly difficult ...
(Date:9/30/2014)... compared with placebo did not reduce hospital length of ... mortality, or the risk of death at 6 months ... ill, according to a study published in JAMA ... coincide with its presentation at the European Society of ... prevalence of low vitamin D levels has been confirmed ...
(Date:9/30/2014)... Youth Town’s annual BBQ/Music Festival will take ... p.m. at the Youth Town campus (3641 Youth Town ... family-oriented festival, which will offer music, food and games. ... car show, arts and crafts fair, music, championship barbeque ... Lightning McQueen and Mater from the hit Disney movie ...
(Date:9/30/2014)... September 30, 2014 Top10inaction.com, one of ... on ranking and reviewing all essential categories in daily ... announced the best liquid foundation at http://top10inaction.com/liquid-foundations/ , ... is named as the best foundation of them all. ... well as high end brands, hence customers have more ...
(Date:9/30/2014)... September 30, 2014 3M has added four ... high bond tapes. 3M 5906 , 3M 5907 ... are conformable VHBs which help create the strongest bond possible ... are used for bonding to difficult surfaces such as paints, ... 5906, 5907, 5908, and 5905 are designed specifically for electronic ...
Breaking Medicine News(10 mins):Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 2Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 3Health News:High-dose vitamin D for ICU patients who are vitamin D deficient does not improve outcomes 2Health News:Yves Saint Laurent is Named As Best Liquid Foundation 2014 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3
... The University of Pittsburgh Cancer Institute (UPCI) today ... F. Shapira BRCA Cancer Research Program. BRCA 1 and ... the risk of breast, prostate, ovarian and pancreatic cancers. ... this research program to UPCI, said Ronald Herberman, M.D., ...
... people on trial were granted the right to an interpreter ... by UCL (University College London) scientists. The use of family ... teachers and eventually written testimony, which may have disadvantaged the ... British Sign Language was emerging. , The study, ...
... debt and expands available credit facility, HATBORO, ... leading technology provider of enterprise mobility solutions for,the ... has,completed a senior debt financing of up to ... HTGC )., (Logo: http://www.newscom.com/cgi-bin/prnh/20071101/NETH165LOGO ...
... country and online offer opportunity to save a life, ... of adding,46,000 new members to the marrow Registry during ... Marrow Donor Program,s largest,annual awareness campaign, kicks off today., ... other,life-threatening diseases, a marrow transplant offers a second chance ...
... and atypical cells also indicate high risk of second cancer, study ... have been diagnosed with breast cancer, having a known mutation in ... second cancer, and many of these women choose to have their ... However, new research suggests that women who don,t have ...
... May 5 Facet Solutions, Inc., a privately,held ... announced the successful completion of a scientific,evaluation for ... The study,evaluated the combination of Facet Solutions, Anatomic ... device in a,finite element model. The details of ...
Cached Medicine News:Health News:Research program focuses on genetic mutations and cancer risk 2Health News:'Deaf by God' tried in Old Bailey records 2Health News:'Deaf by God' tried in Old Bailey records 3Health News:InfoLogix Completes $25 Million Senior Debt Financing 2Health News:InfoLogix Completes $25 Million Senior Debt Financing 3Health News:National Marrow Donor Program(R) Kicks off National Awareness Campaign 2Health News:National Marrow Donor Program(R) Kicks off National Awareness Campaign 3Health News:BRCA Mutations Don't Spot All High-Risk Women 2Health News:BRCA Mutations Don't Spot All High-Risk Women 3Health News:Facet Solutions, Inc. Completes Combination Facet Joint and Disc Replacement Study 2
... The PRO6000 power supply ... Thermo's power supply product offering. ... proteomic and genomic electrophoresis. This ... to proteomic applications such as ...
... voltage power supply, the 105 is very simple ... switch control the output, which is variable in ... two-position switch toggles the bright LED display from ... is equipped with an over current detector for ...
... supply is capable of producing up to 250 ... operates in constant voltage or constant current with ... over from one mode of operation to the ... A dual function, auto ranging 24-hour up/down ...
... is designed for horizontal and vertical gel ... be accomplished. In this power supply model, ... current or constant voltage. Four sets of ... connected simultaneously. This power supply's light, compact ...
Medicine Products: